Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD

NCT03267108 is registered in ClinicalTrials.gov with Bellerophon Pulse Technologies as lead sponsor.

NCT NCT03267108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03267108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Lead sponsor
Bellerophon Pulse Technologies
Phase
Phase 3
Overall status
Terminated
Start date
December 14, 2020
Completion date
June 30, 2023
Enrollment
145 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary fibrosis, pulmonary hypertension